“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Sunday, August 31, 2025

Celgene Corporation


Celgene Corporation products


A

  • Abraxane® — paclitaxel protein-bound particles for injectable suspension

    • Indication: various solid tumors (e.g., breast, pancreatic, lung cancers)

I

  • Idhifa® — enasidenib

    • Indication: relapsed or refractory acute myeloid leukemia (AML) with IDH2 mutation

  • Imnovid® — pomalidomide (also known as Pomalyst®)

    • Indication: multiple myeloma after at least two prior therapies

  • Istodax® — romidepsin

    • Indication: cutaneous and peripheral T‑cell lymphoma

  • Otezla® — apremilast (sold to Amgen during BMS acquisition)

    • Indication: psoriasis and psoriatic arthritis

P

  • Pomalyst® — pomalidomide (duplicate of Imnovid marketed under different names)

R

  • Revlimid® — lenalidomide

    • Indications: multiple myeloma (with dexamethasone), 5q‑deleted myelodysplastic syndromes (MDS)

  • Reblozyl® — luspatercept‑aamt

    • Indication: anemia in beta-thalassemia or MDS

  • Revlimid duplicate; see above.

T

  • Thalomid® — thalidomide

    • Indications: erythema nodosum leprosum (ENL), and, in combination with dexamethasone, multiple myeloma

V

  • Vidaza® — azacitidine

    • Indication: MDS and certain leukemias



on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)